Friday, May 1, 2020 NIAID Now: New NIAID Study Examines Immune Responses in People Hospitalized with COVID-19 Today, a new NIAID-supported study has begun to track the immune responses of people hospitalized with COVID-19 in 10 research sites across the United States. Investigators in NIAID's Human Immunology Project Consortium (HIPC) in collaboration with researchers in the Asthma and Allergic Diseases Clinical Research Consortium (AADCRC) and other NIAID-funded groups, aim to determine how certain immunological measures correspond to, or may even predict, the clinical severity of COVID-19. Data collected in the Immunophenotyping Assessment in a COVID-19 Cohort, or IMPACC, study will help inform recommendations for COVID-19 care and, hopefully, identify new targets and optimal timing for experimental treatments. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107